Windlas Biotech Limited (NSE:WINDLAS)

Market Cap	19.49B
Revenue (ttm)	7.60B
Net Income (ttm)	609.94M
Shares Out	20.90M
EPS (ttm)	28.87
PE Ratio	32.30
Forward PE	n/a
Dividend	5.80 (0.62%)
Ex-Dividend Date	Sep 17, 2024

Volume	34,762
Average Volume	64,138
Open	906.00
Previous Close	930.65
Day's Range	906.00 - 935.45
52-Week Range	659.00 - 1,198.25
Beta	0.31
RSI	48.07
Earnings Date	May 16, 2025

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO solutions, including product development, licensing, and commercial manufacturing of complex drugs and dosage forms. It also produces nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprising fixed dosage combinations, fixed dosage plus modifie...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,154
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WINDLAS

Financial Performance

In 2024, Windlas Biotech's revenue was 7.60 billion, an increase of 20.43% compared to the previous year's 6.31 billion. Earnings were 609.94 million, an increase of 4.82%.